June 13, 2025

Influenza

Oseltamivir Treatment vs Supportive Care for Seasonal Influenza Requiring Hospitalization In Adults with Influenza Requiring Admission to Hospital
This study sought to determine if oseltamivir treatment within the first two days of admission, when compared with supportive care without oseltamivir, is associated with a decreased risk of death in hospital. 11,073 patients, with 7,632 patients in the oseltamivir and 3,441 patients in the supportive care groups. In hospital, 268 patients (3.5%) in the oseltamivir and 168 patients (4.9%) in the supportive care groups died, respectively, with an adjusted risk difference of −1.8% (95% CI, −2.8% to −0.9%; P < .001). The oseltamivir treatment group was more likely to be discharged alive (adjusted subdistribution hazard ratio, 1.20; 95% CI, 1.15 to 1.25; P < .001). After discharge, 645 patients (8.5%) and 336 patients (9.8%) were readmitted in the oseltamivir and supportive care groups, respectively, with an adjusted risk difference of −1.5% (95% CI, −2.8% to −0.2%; P = .02).

COVID: The Late Phase/PASC/Long COVID

Long-term Outcomes of Patients with Pre-existing Coronary Artery Disease after SARS-CoV-2 Infection
Patients with pre-existing coronary artery disease (CAD) were classified as COVID+ or COVID– based on the polymerase-chain-reaction test in the Montefiore Health System between March 11, 2020, and January 12, 2024. The final cohorts comprised 380 hospitalized with COVID-19, 1,702 non-hospitalized with COVID-19, 7,264 contemporary COVID– controls, and 8,492 historical controls (January 1, 2016–December 31, 2019). Primary outcomes were all-cause mortality, new-onset congestive heart failure (CHF), myocardial infarction (MI), stroke, and major adverse cardiovascular events (MACE).Compared to contemporary controls, patients hospitalized with COVID-19, but not patients not hospitalized with COVID-19, had higher future risk of MACE (adjusted HR = 1.58 [1.38, 1.80]), mortality, CHF, MI, and stroke up to four years post-infection (p < 0.05).